Dr. Ameet Nathwani was appointed as Executive Vice President, Group Chief Medical Officer and Global Head of Medical Function in May, 2016.

Dr. Nathwani is responsible for enterprise-wide medical, patient safety, medical quality assurance and will insure the highest standard of transparency and compliance in Sanofi’s interactions with healthcare providers, patients and medical organizations.

A U.K. citizen, born in Uganda and educated in the U.K., Dr. Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.

Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
SPEAKERS BIOGRAPHIES

Dr. Pietro Antonio Tataranni, MD is currently Senior Vice President, Head of Global Medical Affairs, Diabetes & Cardiovascular Business Unit, in charge of medical strategy worldwide and operations for mature markets at sanofi. Previous responsibilities within the group included the roles of Vice President Global Medical Affairs, Medical Director Europe, Vice President for the Metabolism Medical Unit in the US affiliate (2006-2008) and Medical Director for the Metabolism Franchise (2005-2006). Between 1999 and 2004 he was Head of the Obesity, Diabetes and Energy Metabolism Unit at the Phoenix Epidemiology and Clinical Research Branch of the National Institutes of Health in the US and Director of the Clinical Research Center at the same institution from 2000 through 2004.

Dr. Tataranni is an avid researcher who has published and lectured extensively at national and international meetings on obesity, diabetes and their cardiometabolic complications. Professional awards presented to Dr. Tataranni include the NIH Fellowship Award for Research Excellence (FARE) in 1998 and the North American Association for the Study of Obesity (NAASO)-Lilly Scientific Achievement Award in 2004.

Dr Tataranni is a native of Italy. He graduated from Catholic University School of Medicine in Rome in 1990 and went on to receive a specialty diploma in Endocrinology, Metabolic Diseases and Diabetes at this University. He has authored more than 100 original manuscripts, in addition to contributing to numerous review articles and book chapters. Please check complete profile on LinkedIn and ResearchGate.
Bernard is leading four teams in Sanofi: real world evidence and outcome research, medical science and the processes attached to the data generation, patient centricity, patient solutions, pharmaco-epidemiology.

Bernard is a Medical Doctor trained in Liver diseases and Gastroenterology in Paris from 1984 to 1991, Bernard joined Astra in 1991 as responsible for GI clinical and medical affairs programs in the French Affiliate. From 1994 to 2001 Bernard occupied different clinical research roles based in Sweden (Goteborg) and in the USA (Philadelphia). In 2001, Bernard was appointed head of the French AstraZeneca affiliate Medical Affairs team. From 2005 to 2011, Bernard worked as Regional Medical Director in Belgium.

The importance of real life data to support HCP and local payers’ decision making justified building a regional center of excellence focusing of real life studies.

From 2011 to 2014, Bernard moved to London and led to the Global Medical Affairs team implementing different transformation programs supporting emerging projects and late stage AZ brands. Since 2014, Bernard focused on translational research and health informatics, of particular interest are ways to improve medical care through improving the generation and dissemination of validated health care knowledge.